Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.47 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669546 | 0.90 | CYP24A1 (0.53) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL10593756 | 0.89 | CYP24A1 (0.46) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL10593732 | 0.85 | CYP24A1 (0.52) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL15874767 | 0.84 | CYP24A1 (0.60) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL4366122 | 0.84 | CYP24A1 (0.60) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL3119314 | 0.82 | CYP24A1 (0.47) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL10597721 | 0.82 | CYP24A1 (0.47) | CYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL13885522 | 0.82 | CYP24A1 (0.48) | CYP24A1CYP27A1CYP26A1CYP19A1DDB1 | |
| SCHEMBL3654990 | 0.82 | CYP24A1 (0.48) | CYP24A1CYP27A1CYP26A1CYP19A1DDB1 | |
| SCHEMBL10596034 | 0.81 | CYP24A1 (0.52) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497386-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| CN-119161384-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-112105607-B | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-112105607-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS HEALTH, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP26A1 226/4885 |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP26A1 226/4885 |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP26A1 226/4885 |
| US-11384068-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP26A1 226/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP26A1 226/4885 |
| US-12497386-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | CYP24A1 117/4885CYP27A1 232/4885CYP26A1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.